What you should know about the latest pneumococcal vaccine

P. J. Gavin*, Ram Yogev, Tina Quanbee Tan

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Streptococcus pneumoniae continues to be a common cause of pneumonia, bacteremia, acute otitis media (AOM), and sinusitis. This pathogen causes about 40,000 deaths annually in the United States. The 23-valent pneumococcal polysaccharide vaccine effectively prevents S pneumoniae infection in many patient populations, but it is not recommended for children younger than 2 years - a group that has a particularly high incidence of invasive pneumococcal disease. Recently, a heptavalent pneumococcal conjugate vaccine (PCV) was approved for infants and toddlers, beginning at 2 months of age. This vaccine contains the 7 serotypes that account for most cases of invasive pneumococcal disease and AOM in US children and has an efficacy rate of 97% against invasive disease caused by these serotypes. The PCV has demonstrated an excellent safety profile, with no significant adverse effects.

Original languageEnglish (US)
Pages (from-to)699-707
Number of pages9
JournalJournal of Respiratory Diseases
Issue number11
StatePublished - Jan 1 2000

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'What you should know about the latest pneumococcal vaccine'. Together they form a unique fingerprint.

Cite this